局部晚期喉咽癌的非手术治疗:网状Meta分析
结果显示,顺铂同步放化疗在喉保留方面排名最高,诱导PF→RT可能带来总生存获益,序贯TPF→RT在局部区域控制方面表现最佳。
要点
- 顺铂同步放化疗是喉保留最一致的策略(SUCRA 0.73)。
- 诱导PF→RT的总生存获益概率最高(SUCRA 0.68),但可信区间重叠。
- 序贯TPF→RT在局部区域控制方面排名最佳(SUCRA 0.94)。
核心结论
- 顺铂同步放化疗仍是最一致的器官保留策略。
- 诱导PF→RT可能提供适度总生存获益,序贯TPF→RT在局部区域控制方面更优。
- 治疗应根据合并症、功能目标和机构经验个体化,并需头对头试验及免疫/靶向药物的整合。
研究设计与样本
- 研究对象为局部晚期或可切除喉/下咽鳞状细胞癌成人患者。
- 检索截至2025年6月30日发表的RCT,通过系统数据库和试验注册库检索及参考文献筛选。
主要发现
- 喉保留方面,顺铂同步放化疗SUCRA 0.73排名最高,其次为诱导TPF→RT(0.72)和RT+西妥昔单抗(0.61)。
- 所有非手术策略在喉保留方面均优于手术加术后放疗(HR 0.34;95%CI 0.20-0.58)。
- 总生存方面,诱导PF→RT的获益概率最高(SUCRA 0.68),领先方案间可信区间重叠。
- 局部区域控制方面,诱导TPF→RT排名最佳(SUCRA 0.94)。
- 敏感性分析支持结果的稳健性。
关键数值与推荐
- 喉保留SUCRA:顺铂同步放化疗0.73,诱导TPF→RT 0.72,RT+西妥昔单抗0.61。
- 非手术策略 vs 手术+术后RT的喉保留HR 0.34(95%CI 0.20-0.58)。
- 总生存SUCRA:诱导PF→RT 0.68;局部区域控制SUCRA:诱导TPF→RT 0.94。
临床怎么用
- 顺铂同步放化疗可作为局部晚期喉/下咽鳞癌器官保留的首选非手术策略。
- 对总生存有更高需求且可耐受诱导治疗者,可考虑诱导PF→RT。
- 对局部区域控制要求高者,序贯TPF→RT可能更优。
- 决策需结合合并症、功能目标及机构经验个体化。
局限性
- 领先方案间总生存可信区间重叠,需谨慎解读排名。
- 证据水平为N/A,需头对头试验验证。
- 未纳入免疫治疗或靶向药物的直接比较数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the efficacy of non-surgical organ-preservation strategies for locally advanced or resectable laryngeal and hypopharyngeal squamous cell carcinoma (SCC). DATA SOURCES: Randomized controlled trials (RCTs) published through June 30, 2025, identified via systematic database and trial-registry searches and reference screening. REVIEW METHODS: We performed a systematic review and Bayesian random-effects network meta-analysis of RCTs enrolling adults with locally advanced/resectable laryngeal/hypopharyngeal SCC. Treatments included surgery plus postoperative radiotherapy (RT), RT alone, concurrent cisplatin-based chemoradiotherapy (CTRT), induction chemotherapy followed by RT/CTRT, altered-fractionation RT, dose-modified CTRT, and RT ± cetuximab. Effect estimates were synthesized as hazard ratios (HRs) and odds ratios (ORs). Treatments were ranked using surface under the cumulative ranking curve (SUCRA). RESULTS: Fifteen RCTs (n = 4395; 13 strategies) were included. For laryngeal preservation, cisplatin-based CTRT ranked highest (SUCRA 0.73), followed by induction TPF → RT (0.72) and RT + cetuximab (0.61). All non-surgical strategies outperformed surgery plus postoperative RT for laryngeal preservation (HR 0.34; 95% CI, 0.20-0.58). For overall survival, induction PF → RT showed the highest probability of benefit (SUCRA 0.68), with overlapping credible intervals across leading regimens. For locoregional control, induction TPF → RT ranked best (SUCRA 0.94). Sensitivity analyses supported robustness. CONCLUSION: Concurrent cisplatin-based CTRT remains the most consistent organ-preservation strategy. Induction PF → RT may offer modest overall survival benefit, whereas sequential TPF → RT appears superior for locoregional control. Treatment should be individualized by comorbidity, functional goals, and institutional expertise; head-to-head trials and incorporation of immunotherapy/targeted agents are needed. LEVEL OF EVIDENCE: N/A.
引用
- Capriotti V, Cin ED, De Stefani A, et al. Treatment of Locally Advanced Layngohypopharyngeal Cancers: A Network Meta-Analysis. Laryngoscope. 2026. PMID: 42528018. doi:10.1002/lary.70780
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。